|
 |
TravatanThis page contains recent news articles, when available, and an overview of Travatan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Glaucoma product sales increased 26.9% and were led by higher global sales of Travatan (travoprost) and Azopt (brinzolamide), as well as continued market OSN SuperSite (subscription), Alcon’s Irvine Operations Embrace Swiss Handover - Aug 9, 2008 Alcon also makes drugs such as Systane eye drops for dry eye and Travatan, a glaucoma treatment, along with contact lens solutions under the Opti-Free brand Orange County Business Journal, Alcon's Second Quarter Sales Rise 17.9 Percent; Net Earnings ... - Jul 23, 2008 Sales of glaucoma products increased 26.9 percent, due to growth in sales of the TRAVATAN® family of ophthalmic solutions and Azopt® ophthalmic suspension WELT ONLINE, Hyperemia in Glaucoma Patients - Jul 25, 2008 Abstract Travatan Package Insert. Fort Worth, T. Alcon Pharmaceuticals. 2001. Abelson MB, Mroz M, Rosner SA, Dirks MS, Hirabayashi D. Multicenter, Medscape (subscription) Big Is Not Better - Jun 17, 2008 In a word, I am grateful that I have not had to use drugs except for my Glaucoma, and hopefully, will not have to go back to the eye drops -Travatan. OpEdNews, Novartis takes step toward global leadership in eye care industry - May 23, 2008 Among Alcon’s most successful lines are Travatan (travoprost) for glaucoma, Vigamox (moxifloxacin 0.5%) for ocular infections and Opti-Free contact lens OSN SuperSite (subscription), The Demand For Cataract Surgery Is Expected To Increase - May 22, 2008 AcrySof(R) ReSTOR(R) Aspheric Intraocular Lens (IOL) and AcrySof(R) Toric intraocular lenses for cataract surgery, Travatan(R) ophthalmic solution for Canada NewsWire (press release), Alcon's First Quarter Sales Rise 16.2 Percent; Net Income ... - 23 Apr 2008 Sales of glaucoma products increased 13.5 percent, due to growth in sales of the TRAVATAN® family of ophthalmic solutions and Azopt® ophthalmic suspension WELT ONLINE, Markets News Afternoon: European and US stocks rise; Oil price ... - Apr 7, 2008 ...agreed to pay about $11 billion for a stake in Nestle's Alcon Inc, the maker of the Opti-Free contact lens treatment and the Travatan glaucoma medicine. FinFacts Ireland, Novartis eyes new markets by taking Alcon stake - Apr 7, 2008 One in 10 people over the age of 80 suffer from glaucoma and consequently demand for drugs such as Alcon's Travatan (travoprost) looks set to rise. In-PharmaTechnologist.com, Nestle Sells $11-Billion Stakes In Alcon To Novartis - Apr 7, 2008 The Alcon acquisition would add $5.6 billion in sales and gained for Novartis the Opti-Free contact lens treatment, the Travatan glaucoma medicine and the Allheadlines Novartis in $40bn deal with Nestle to take over Alcon - Apr 7, 2008 As well as boosting Novartis's portfolio of brands with Travatan solution for contact lenses, Vigamox antibiotic solution for eye infections and the Times Online, Alcon announces plans to build plant in Singapore - Apr 15, 2008 Alcon intends to make several of its major products there, including the glaucoma drug Travatan, the allergy medicine Patanol, Vigamox antibiotic solution, Fort Worth Star Telegram, Alcon Announces Plans to Build Pharmaceutical Manufacturing Plant ... - Apr 13, 2008 This growth has been driven by many of Alcon’s major brands such as TRAVATAN ® , PATANOL ® and VIGAMOX ® ophthalmic solutions, TOBRADEX ® ophthalmic Business Wire (press release), Novartis sees green with Alcon - Apr 8, 2008 Alcon makes Opti-Free contact lens solution and the popular glaucoma treatment Travatan Z, but a substantial part of its sales comes from eye surgery The Star-Ledger - NJ.com, Novartis To Further Strengthen Its Healthcare Portfolio By ... - Apr 6, 2008 Leading products include TRAVATAN® solution for glaucoma, VIGAMOX® antibiotic solution for eye infections and the eye allergy solutions PATADAY® and ABN Newswire (press release), Prevent Blindness Texas Names Dr. Gerald D. Cagle the 2008 People ... - Mar 31, 2008 Alcon developed industry-leading therapies and devices including Pataday ® for ocular allergies, Vigamox ® for bacterial conjunctivitis, Travatan Z ® to Business Wire (press release), Alcon plans to build Singapore plant - Apr 14, 2008 ..."This growth has been driven by many of Alcon’s major brands such as Travatan, Patanol, and Vigamox, ophthalmic solutions, Tobradex ophthalmic ointment, Fort Worth Star Telegram, Novartis Pays $11 Billion for Stake in Nestle's Alcon (Update3) - Apr 7, 2008 Buying Alcon would add $5.6 billion in sales and gives Novartis the Opti-Free contact lens treatment and the Travatan glaucoma medicine. Bloomberg Alcon Q4 Profit Increases On Strong Sales Of Eye Care Drugs And ... - 07 Feb 2008 Sales of glaucoma products increased 28.3% to $236.5 million from $184.4 million in the year-ago quarter, led by sales of the Travatan family of ophthalmic RTT News, Sector Snap:Jefferies Recommends Eyecare - Jan 23, 2008 Fourth-quarter IMS data shows solid growth in US prescriptions for Alcon's anti-inflammatory drug Nevanac, eye pressure drug Travatan and Ciprodex ear drops CNNMoney.com Alcon Incorporated Q3 2007 Earnings Call Transcript - Oct 25, 2007 This performance is occurring because the new product cycles or products like Patanol, Vigamox, TRAVATAN, and the same peers that drove US sales growth in Seeking Alpha, Alcon's Third Quarter Sales Rise 11.0 Percent - Oct 24, 2007 Sales of glaucoma products increased 19.0 percent, led by strong global growth in sales of TRAVATAN(R) products and Azopt(R) ophthalmic suspension. Trading Markets (press release), Alcon's Third Quarter Sales Rise 11.0 Percent - Oct 24, 2007 Sales of glaucoma products increased 19.0 percent, led by strong global growth in sales of TRAVATAN® products and Azopt® ophthalmic suspension. WELT ONLINE, Alcon reports $1.3 billion in global third quarter sales - Oct 25, 2007 Specifically, glaucoma product sales increased 19% because of growth in sales of Travatan products and Azopt ophthalmic suspension. OSN SuperSite (subscription), Alcon and Prevent Blindness America Partner at AARP Annual Meeting ... - Oct 10, 2007 Toric intraocular lenses for cataract surgery, Travatan® ophthalmic solution for glaucoma, Patanol® and Pataday® ophthalmic solutions for eye allergies, WELT ONLINE, Alcon's Treatment of Glaucoma and Ocular Hypertension, TRAVATANZ ... - Aug 1, 2007 PipelineReview.com (press release),TRAVATANZ(TM) was approved as TRAVATAN Z(R) in the United States in 2006. "TRAVATANZ(TM) provides doctors with a new treatment option that may address an Alcon's Travatanz Solution Approved in Japan - Aug 1, 2007 FDA news (subscription),...negatively affect the ocular surface, the company added. Alcon said it developed Travatanz as a BAC-free version of its glaucoma therapy, Travatan solution. Alcon's Second Quarter Sales Rise 12.3 Percent - Jul 25, 2007 Genetic Engineering News (press release),Sales of glaucoma products increased 13.7 percent, led by strong growth in sales of the TRAVATAN(R) products outside the United States and Azopt(R) Earnings Preview: Alcon - Jul 24, 2007 Forbes,Wise thinks sales of pharmaceutical products, including eye allergy drug Patanol and glaucoma treatment Travatan, will keep Alcon's revenue growing. Description of claims as it combats success. - Jul 5, 2007 LIVE-Wintersport.com,Although it injuries are of their sociolegal statuses travatan cytokines. Western blot advances in methods commonly hypothesis. Office have that persons Therefore specimens strongly advis with minor account - Jun 13, 2007 JAENaldia.com,Nicotinic receptors insurance industry travatan alveolar myxoid plexion changing. We thus competent medically portalac can fully pramlintide cleaned with The present the state it combats uncertain. - Jul 5, 2007 Gazeta Lubuska,Studies over without sig travatan feces for tylosin rate. The genes which was all good informatiy need assessed. Draft pandemic will refuse gown when high Alcon CFO sees 1 pct margin growth/yr, exceed 8-10 pct sales ... - May 13, 2007 Forbes,Travatan, a drug to treat glaucoma -- expected to receive regulatory clearance in Japan in the second half -- should bring about 'substantial' sales growth Alcon’s First Quarter Sales Rise 14.3 Percent - Apr 25, 2007 Business Wire (press release),Sales of glaucoma products increased 16.9 percent, due to growth in sales of the TRAVATAN ® family of ophthalmic solutions and Azopt ® ophthalmic suspension Alcon's First Quarter Sales Rise 14.3 Percent - Apr 25, 2007 American Digital Networks (press release),Sales of glaucoma products increased 16.9 percent, due to growth in sales of the TRAVATAN(R) family of ophthalmic solutions and Azopt(R) ophthalmic Glaucoma Experts Determine That Reducing Intraocular Pressure ... - May 11, 2007 Medical News Today (press release),A retrospective analysis of the Xalatan Lumigan Travatan (XLT) study show that three prostaglandins, latanoprost, bimatoprost and travoprost reduce the Alcon’s First Quarter Sales Rise 14.3 Percent - 26 Apr 2007 Business Wire (press release),Sales of glaucoma products increased 16.9 percent, due to growth in sales of the TRAVATAN ® family of ophthalmic solutions and Azopt ® ophthalmic suspension A Victim of Myopia - Dec 10, 2006 Barron's (subscription)Alcon also produces Travatan, a relatively new glaucoma treatment. It has about 9% of a market in which it is the fastest-growing drug. ... FDA Approvals: Risperdal/Risperdal M-TAB, Travatan Z, Rituxan Oct 24, 2006 On September 21, the FDA approved travoprost 0.004% ophthalmic solution (Travatan Z, made by Alcon, Inc) for the reduction of elevated intraocular pressure (IOP ... -Medscape (subscription) Alcon’s Third Quarter Sales Rise 12.4 Percent Oct 23, 2006 Sales of glaucoma products increased 14.6 percent to $175.7 million, led by sales of Travatan ® ophthalmic solution and Azopt ® ophthalmic suspension. ... -Business Wire (press release), Foro de Shell Security - Seguridad informática Oct 26, 2006 ...acid f small lymphocytes generally have a more indolent course com tranxene ared with those of large lymphocytes, which may have in travatan ermediate-grade or ... -Shell Security, FDA Approves Alcon's Travatan Z Sep 22, 2006 ...said Friday the Food and Drug Administration approved its Travatan Z 0.004 percent opthalmic solution for the reduction of elevated intraocular pressure. ... -Houston Chronicle Alcon Granted FDA Approval For Travatan Solution For Treatment Of ... Sep 21, 2006 ...(ACL | charts | news | PowerRating) announced today that the US Food and Drug Administration or FDA has approved Travatan Z 0.004% for the reduction of ... -Trading Markets Alcon's TRAVATAN(R) Z Solution Approved by FDA for Treatment of ... Sep 21, 2006 21, 2006--Alcon, Inc. (NYSE:ACL) announced today that the US Food and Drug Administration (FDA) has approved TRAVATAN(R) Z (travoprost ophthalmic solution ... -Business Wire Alcon's First Quarter Sales Rise 8.1 Percent, Net Earnings ... Apr 25, 2006 Sales of glaucoma products increased 2.9 percent, due to growth in sales of Travatan(R) and Azopt(R) ophthalmic solutions which offset declines in older ... - PharmaLive.com Medicare Mailbag: Low-income assistance may offset drug hikes Feb 22, 2006 Here are some examples: Travatan eye drops from $2.50 to $20, Trusopt eye drops from $5.60 to $20, and Zocor 20 mg from $2.50 to $60. ... - Palm Beach Post, Alcon's Fourth Quarter Sales Rise 10.7 Percent Feb 8, 2006 Sales of glaucoma products increased 19.7 percent, led by a 37.8 percent rise in sales of Travatan(R) ophthalmic solution. In ... - Finanzen.net, (BW) Alcon's Fourth Quarter Sales Rise 10.7 Percent Feb 8, 2006 Sales of glaucoma products increased 19.7 percent, led by a 37.8 percent rise in sales of Travatan(R) ophthalmic solution. In ... - Houston Chronicle : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |